Table 4:
7-yr disease-free survival (DFS), cumulative incidence of breast cancer-free interval (BCFI), and distant recurrence according to select patient characteristics and treatment: NSABP B-42
| Endpoint | 7-Yr DFS (%) | 7-Yr Cum. Incidence BCFI Event (%) | 7-Yr Cum. Incidence Distant Recurrence (%) | ||||
|---|---|---|---|---|---|---|---|
| Characteristic | Placebo | Letrozole | Placebo | Letrozole | Placebo | Letrozole | |
| Pathologic Nodal Status | Negative | 83.4 (80.9, 85.7) | 86.5 (84.2,88.5) | 8.2 (6.5, 10.0) | 5.3 (4.0, 6.8) | 3.6 (2.5, 4.9) | 2.2 (1.4, 3.2) |
| Positive | 78.4 (75.2, 81.3) | 82.4 (79.4, 85.0) | 12.4 (10.1, 15.0) | 8.7 (6.8, 10.8) | 8.7 (6.8, 10.9) | 6.3 (4.7, 8.2) | |
| Prior Tamoxifen | No | 79.8 (77.1, 82.1) | 82.0 (79.4, 84.3) | 9.9 (8.2, 11.8) | 6.8 (5.4, 8.5) | 5.9 (4.5, 7.4) | 3.6 (2.6, 4.9) |
| Yes | 83.7 (80.6, 86.3) | 88.8 (86.2, 91.0) | 10.0 (7.8, 12.5) | 6.5 (4.8, 8.5) | 5.6 (4.0, 7.6) | 4.4 (3.1, 6.1) | |
| Lowest BMD T score | ≤−2.0 | 77.9 (73.4, 81.7) | 84.3 (80.2, 87.6) | 9.3 (6.9, 12.3) | 5.7 (3.6, 8.5) | 7.3 (5.1, 9.9) | 2.7 (1.5, 4.6) |
| >−2.0 | 82.4 (80.1, 84.4) | 84.9 (82.8, 86.7) | 10.2 (8.5, 11.9) | 7.1 (5.8, 8.5) | 5.3 (4.1, 6.6) | 4.3 (3.3, 5.5) | |
| Age, years | < 60 | 86.0 (82.9, 88.6) | 88.1 (85.2, 90.5) | 9.5 (7.3, 12.1) | 6.7 (4.9, 8.9) | 5.9 (4.2, 8.0) | 4.3 (2.9, 6.2) |
| ≥60 | 78.8 (76.3, 81.2) | 83.0 (80.6, 85.1) | 10.2 (8.5, 12.1) | 6.7 (5.4, 8.3) | 5.7 (4.4, 7.2) | 3.7 (2.8, 4.9) | |
| Surgery Type | Lumpectomy | 83.4 (80.9, 85.6) | 85.7 (83.3, 87.7) | 8.7 (7.0, 10.5) | 6.2 (4.8, 7.9) | 3.1 (2.2, 4.3) | 2.5 (1.7, 3.5) |
| Mastectomy | 78.0 (74.6, 81.0) | 83.3 (80.3, 85.9) | 12.0 (9.6, 14.6) | 7.5 (5.7, 9.5) | 10.0 (7.8, 12.4) | 6.1 (4.5, 8.1) | |